Condition: Melanoma · Melanoma, Uveal · Head and Neck Cancer · Sponsor: Erasmus Medical Center
Single-centre, first-in-man phase I/II trial to demonstrate safety and efficacy of MAGE-C2/HLA-A2 TCR T cells (MC2 TCR T cells) in advanced melanoma (MEL) and head-and-neck carcinoma (HNSCC).
This description comes directly from the study's public registry record.
A.A.M. van der Veldt, MD, PhD · +31 107041754 · a.vanderveldt@erasmusmc.nl
R. Debets, PhD, Prof · +31 107038307 · j.debets@erasmusmc.nl
Always discuss trial participation with your own doctor first.
| Erasmus Medical Center | Rotterdam, Netherlands | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04729543